RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.
Company Details
- Employees
- 13
- Founded
- 2022
- Address
- 10935 Alexandria Way,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.rybodyn.com/
- HQ
- San Diego, California
Rybodyn Inc. Questions
Rybodyn Inc.'s website is https://www.rybodyn.com/
Rybodyn Inc.'s LinkedIn profile is https://www.linkedin.com/company/rybodyn
Rybodyn Inc. has
13 employees.
View email and phone details for 13
employees at Rybodyn Inc..
Rybodyn Inc.'s industry is
Biotechnology Research
Rybodyn Inc.'s top competitors are
Kisaansay,
Jentic,
Absci,
Indiebio,
Genedant Capital,
Reactosome,
Rena Labs,
Phase Two Ventures,
Graph,
Kaya Ai.
Rybodyn Inc.'s categories are Biotechnology Research
Rybodyn Inc.'s founding year is 2022
